An Open Label, Single-Arm, Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors.

Trial Profile

An Open Label, Single-Arm, Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2016

At a glance

  • Drugs Mipsagargin (Primary)
  • Indications Liver cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors GenSpera
  • Most Recent Events

    • 26 Apr 2016 Results published in the British Journal of Cancer
    • 08 Sep 2014 According to a GenSpera media release, interim data from this and other Phase II trial (see profile 224742) presented at the 8th International Liver Cancer Association (ILCA) Conference
    • 05 Nov 2013 Status changed from active, no longer recruiting to completed based on final results presented at EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics, according to a GenSpera media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top